comparemela.com
Latest Breaking News On - Concurrent frontline nivolumab and gemcitabine cisplatin - Page 1 : comparemela.com
Frontline Nivolumab Plus Chemotherapy Boosts OS and PFS in Metastatic Urothelial Carcinoma
Concurrent frontline nivolumab and gemcitabine-cisplatin followed by nivolumab maintenance therapy elicited OS and PFS benefits vs gemcitabine-cisplatin alone in patients with previously untreated, metastatic or unresectable urothelial carcinoma.
Netherlands
Amsterdam
Noord-holland
Michiels-van
Netherlands-cancer-institute
Concurrent-frontline-nivolumab-and-gemcitabine-cisplatin
Urothelial-carcinoma
Checkmate-901-study
Nct03036098
Michiels-van-der-heijden
D
vimarsana © 2020. All Rights Reserved.